Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 24Colorectal Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Biliary Tract Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Esophageal Neoplasms 3HER2-positive Gastric Cancer 2Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lung Neoplasms 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1

Interventions

tislelizumab 2Oxaliplatin 2tremelimumab 1olaparib 1durvalumab 1apatinib 1Tegafur 1Immunotherapy, Adoptive 1Dacarbazine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunotherapy × Tegafur × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡